Literature DB >> 10199949

Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability.

N Delahaye1, S Dinanian, M S Slama, H Mzabi, D Samuel, D Adams, P Merlet, D Le Guludec.   

Abstract

Familial amyloid polyneuropathy (FAP) is a rare and severe hereditary form of amyloidosis, due to nervous deposits of a genetic variant transthyretin produced by the liver and characterized by both sensorimotor and autonomic neuropathy. Left ventricular systolic dysfunction is rare, but conduction disturbances and sudden deaths can occur. The neurological status of the heart has not been elucidated, and an alteration of the sympathetic nerves may be involved. We studied 17 patients (42+/-12 years) before liver transplantation by iodine-123 metaiodobenzylguanidine (MIBG) scintigraphy, heart rate variability analysis, coronary angiography, radionuclide ventriculography, rest thallium single-photon emission tomography (SPET) and echocardiography. Coronary arteries, left ventricular systolic function and rest thallium SPET were normal in all patients. Only mild evidence of amyloid infiltration was found at echocardiographic examination. Cardiac MIBG uptake was dramatically decreased in patients compared with age-matched control subjects (heart-to-mediastinum activity ratio at 4 h: 1.36+/-0.26 versus 1.98+/-0.35, P<0.001), while there was no difference in MIBG washout rate. Heart rate variability analysis showed a considerable scatter of values, with high values in four patients despite cardiac sympathetic denervation as assessed by MIBG imaging. The clinical severity of the polyneuropathy correlated with MIBG uptake at 4 h but not with the heart rate variability indices. Cardiac MIBG uptake and the heart rate variability indices did not differ according to the presence or absence of conduction disturbances. Patients with FAP have sympathetic cardiac denervation as assessed by MIBG imaging despite a preserved left ventricular systolic function and cardiac perfusion, without correlation with conduction disturbances. Results of the heart rate variability analysis were more variable and this technique does not seem to be the best way to evaluate the extent of cardiac sympathetic denervation in FAP patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10199949     DOI: 10.1007/s002590050406

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  24 in total

Review 1.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

2.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2019-12       Impact factor: 5.952

Review 3.  Targeted Nuclear Imaging Probes for Cardiac Amyloidosis.

Authors:  Paco E Bravo; Sharmila Dorbala
Journal:  Curr Cardiol Rep       Date:  2017-07       Impact factor: 2.931

4.  How to image cardiac amyloidosis.

Authors:  Rodney H Falk; Candida C Quarta; Sharmila Dorbala
Journal:  Circ Cardiovasc Imaging       Date:  2014-05       Impact factor: 7.792

5.  Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers.

Authors:  Eve Piekarski; Renata Chequer; Vincent Algalarrondo; Ludivine Eliahou; Besma Mahida; Jonathan Vigne; David Adams; Michel S Slama; Dominique Le Guludec; Francois Rouzet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-06       Impact factor: 9.236

Review 6.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.

Authors:  Mathew S Maurer; Sabahat Bokhari; Thibaud Damy; Sharmila Dorbala; Brian M Drachman; Marianna Fontana; Martha Grogan; Arnt V Kristen; Isabelle Lousada; Jose Nativi-Nicolau; Candida Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Ronald Witteles; Giampaolo Merlini
Journal:  Circ Heart Fail       Date:  2019-09-04       Impact factor: 8.790

Review 7.  Can Nuclear Imaging Techniques Predict Patient Outcome and Guide Medical Management in Hereditary Transthyretin Cardiac Amyloidosis?

Authors:  Vincent Algalarrondo; Eve Piekarski; Ludivine Eliahou; Dominique Le Guludec; Michel S Slama; François Rouzet
Journal:  Curr Cardiol Rep       Date:  2018-03-24       Impact factor: 2.931

Review 8.  Molecular imaging of amyloidosis: will the heart be the next target after the brain?

Authors:  Wengen Chen; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2012-04       Impact factor: 2.931

Review 9.  FAP neuropathy and emerging treatments.

Authors:  David Adams; Marie Théaudin; Cecile Cauquil; Vincent Algalarrondo; Michel Slama
Journal:  Curr Neurol Neurosci Rep       Date:  2014-03       Impact factor: 5.081

Review 10.  Nuclear imaging for cardiac amyloidosis.

Authors:  Walter Noordzij; Andor W J M Glaudemans; Simone Longhi; Riemer H J A Slart; Massimiliano Lorenzini; Bouke P C Hazenberg; Claudio Rapezzi
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.